Labopharm Reports Results for First Quarter F...(issuance of common shares ...),Health
Navigation Links
Labopharm Reports Results for First Quarter Fiscal 2008
Date:5/8/2008
issuance of common shares 2 115
-------------------------------------------------------------------------
(23) (950)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Foreign exchange gain (loss) on cash held in
foreign currencies 799 (83)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net increase in cash and cash equivalents
during the period 3,828 13,214
-------------------------------------------------------------------------
Cash and cash equivalents, beginning of period 17,173 13,722
-------------------------------------------------------------------------
Cash and cash equivalents, end of period 21,001 26,936
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Cash flows include the following items:
-------------------------------------------------------------------------
Interest paid 523 411
-------------------------------------------------------------------------
Income taxes received - 472
-------------------------------------------------------------------------
-------------------------------------------------------------------------
'/>"/>
| SOURCE Labopharm Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
(Date:11/21/2008)..., Va., Nov. 21 The Gene...e following statement today from,GPhA President a... Commission,(FTC) roundtable on "Emerging Health ...he mere fact that the FTC is conducting this round...suring that consumers have access to safe and,aff...
(Date:11/21/2008)...N, W.Va., Nov. 21 New r... whether a smokeless, spitless tobacco product aim...hers have found that RJ Reynolds, Camel Snus - tou...ion - contains surprisingly high levels of nicotin...han most other snuff products," said Bruce Adkins ...
(Date:11/21/2008)...LAKES, N.J., Nov. 21 Tod...dical intervention in treating 88 percent of patie...of Americans treated for a chronic condition accou...g and 75 percent of all medical costs. A propriet...by Medco Health Solutions, Inc. (NYSE: MHS ) sig...
(Date:11/21/2008)...ov. 21 In a statewide survey, 33 p...stitute for Surgery at Presbyterian Hospital of Da...nnual listing of " Super Doctors ." , , Eac...h Key Professional Media, Inc. to survey more than...Texas to ask, "If you needed medical care, which d...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2[0] GPhA Statement on FTC Roundtable on Biogenerics[0] Experts Say New Tobacco Product Targets Young Adults[0] New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes[0] Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians
...that diabetes and depression go hand in hand for m...ly as non-diabetics to suffer from depression, res...ies the report of this study. Dr. Patrick Lustman ...he Department of Veterans Affairs Medical Center i...
...ERC) in Ahmedabad has alerted the Drug Control Gen...amol. CERC says that the commonly use drug might ...liver failure. CERC Secretary Ashwini Kumar warns ...ntial hazards of paracetamol more so because it is...
...s often show off their sticker tattoos. But adult... permanent reminders throughout life, in different...ere is a darker side to the whole affair. The stu...oos significantly increase the risk of hepatitis C...
...ists plan to launch a human cloning clinic, which ... within 18 months, according to a US infertility s...ogist at the Univeristy of Kentucky, is not medica...reproductive physiology and is an owner and direct...
Other Medicine News:Health News:Scientists plan human cloning clinic in the United States 2(Date:11/20/2008)... The following is being ... , , WHAT: World AIDS Day Audio Media Con...r 25, 2008 , 11:00 a.m. EST , Call-in number...ttps://cc.readytalk.com/r/1xe41i2yre8rs , , ...ber of people newly put on treatment worldwide, ad...
(Date:11/20/2008)...land, November 20 Arpida...ive Drugs Advisory Committee of the,U.S. Food and...st the,approval of intravenous iclaprim, an antib...of patients with complicated skin and skin structu... methicillin-resistant Staphylococcus,aureus (MRS...
(Date:11/20/2008)...v. 20 Radius Health ("Radius") ann...million to its second institutional financing roun...illion and the total amount raised since the compa...titutional investors participated in the financing...ng MPM Capital, The Wellcome Trust, HealthCare Ven...
(Date:11/19/2008)...19 Posit Science Corporation,rese...ety for Neuroscience,Annual Conference in Washing...ing may benefit Baby Boomers. The computerized br...ses adaptive exercises that target auditory and,l...ive generalized,improvements in cognition by impr...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Exelixis Announces First Quarter 2008 Financial Results 1991 1Exelixis Announces First Quarter 2008 Financial Results 1991 2Exelixis Announces First Quarter 2008 Financial Results 1991 3Exelixis Announces First Quarter 2008 Financial Results 1991 4Exelixis Announces First Quarter 2008 Financial Results 1991 5Exelixis Announces First Quarter 2008 Financial Results 1991 6Folic Acid Doesnt Help the Heart 18565 1Folic Acid Doesnt Help the Heart 18565 2Fat 3A Its not what you think 21 3201 1Fat 3A Its not what you think 21 3201 2SEIU Retaliates Against California Caregivers 26 Democratic Reform Movement 18562 1SEIU Retaliates Against California Caregivers 26 Democratic Reform Movement 18562 2[0] Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts[0] Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome[0] Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million[0] New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults
... Pa.--(BUSINESS WIRE)--Apr 18, 2007 - Gemin,X toda...al data,from a study of its lead compound, GX15-07...mia (ALL). The study was discussed in an,oral pres...ociation,for Cancer Research (AACR). According to ...nt activity against ALL blast cells,and also enha...
...NESS WIRE)--Apr 18, 2007 - Idera,Pharmaceuticals, ...,of data for two new potential applications in onc...9 (TLR9) at the Annual Meeting of,the American Ass...Los Angeles, CA, April 14-18, 2007. The first pres...a,s lead oncology candidate,IMO-2055, in combinat...
Other Medicine Technology:Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 2Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 3Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 2Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 3Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 40.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium.
Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm
Straight Iris Scissors; ring handle; 28mm from mid screw to tip; sharp tips; Overall length 110; Also available in 100mm overall length; Stainless Steel
The SURPASS Perfusion Catheter is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion. The SURPASS
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |